肿瘤多药耐药的逆转措施

摘要/Abstract

摘要：化疗是恶性肿瘤的主要治疗方法，而肿瘤多药耐药（MDR）是导致肿瘤化疗失败的重要原因之一。应用化学药物逆转剂、天然药物（中药）逆转剂、免疫治疗、基因治疗、纳米载体给药系统等逆转肿瘤MDR已取得初步进展。但研制出不良反应小、效果好、能够广泛应用于临床的逆转肿瘤MDR药物，仍需要更大努力。

陈颖，张幸平. 肿瘤多药耐药的逆转措施[J]. 国际肿瘤学杂志, 2016, 43(5): 364-367.

Chen Ying, Zhang Xingping. Reversing methods of tumor multidrug resistance[J]. Journal of International Oncology, 2016, 43(5): 364-367.

［1］ Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of Pgp inhibitors: skimming through several generations and scaffolds［J］. Curr Med Chem, 2012, 19(13): 1946-2025. ［2］ Vadlapatla RK, Vadlapudi AD, Pal D, et al. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes［J］. Curr Pharm Des, 2013, 19(40): 7126-7140. ［3］ Wu Q, Yang Z, Nie Y, et al. Multidrug resistance in cancer chemotherapeutics: mechanisms and Lab approaches［J］. Cancer Lett, 2014, 347(2): 159-166. DOI: 10.1016/j.canlet.2014.03.013. ［4］ Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer［J］. Biotechnol Adv, 2013, 31(8): 1397-1407. DOI: 10.1016/j.biotechadv.2013.06.004. ［5］ Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice［J］. Oncologist, 2003, 8(5): 411-424. ［6］ Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 570-594. ［7］ Tang R, Faussat AM, Perrot JY, et al. Zosuquidar restores drug sensitivity in Pglycoprotein expressing acute myeloid leukemia (AML)［J］. BMC Cancer, 2008, 8(8): 51. DOI: 10.1186/14712407851. ［8］ Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of Pglycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebocontrolled trial of the Eastern Cooperative Oncology Group 3999［J］. Blood, 2010, 116(20): 4077-4085. DOI: 10.1182/blood201004277269. ［9］ Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 609-620. ［10］袁斐, 白钢钢, 苗筠杰, 等. 中药逆转肿瘤细胞多药耐药的研究进展［J］. 中草药, 2014, 45(6): 857-863. DOI: 10.7501/j.issn.02532670.2014.06.023. ［11］ Lu WD, Qin Y, Yang C, et al. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo［J］. Clinics (Sao Paulo), 2013, 68(5): 694-701. DOI: 10.6061/clinics/2013(05)18. ［12］ Guo H, Jiang W, Liu W, et al. Extracellular domain of 41BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by antiCD3 x antiPgp bispecific diabody against human multidrugresistant leukemia［J］. Cell Immunol, 2008, 251(2): 102-108. DOI: 10.1016/j.cellimm.2008.04.006. ［13］ Grodzovski I, Lichtenstein M, Galski H, et al. IL2granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3independent apoptotic pathway［J］. Int J Cancer, 2011, 128(8): 1966-1980. DOI: 10.1002/ijc.25527. ［14］ Mizukoshi E, Nakagawa H, Kitahara M, et al. Phase Ⅰ trial of multidrug resistanceassociated protein 3derived peptide in patients with hepatocellular carcinoma［J］. Cancer Lett, 2015, 369(1): 242-249. DOI: 10.1016/ j.canlet.2015.08.020. ［15］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line［J］. DNA Cell Biol, 2011, 30(6): 413-418. DOI: 10.1089/dna.2010.1143. ［16］揭惠, 酉明巧, 刘辉, 等. 肿瘤多药耐药的发生机制及逆转策略［J］. 中华中医药学刊, 2013 (7): 1686-1690. ［17］ Binkhathlan Z, Lavasanifar A. Pglycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives［J］. Curr Cancer Drug Targets, 2013, 13(3): 326-346. ［18］ Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)［J］. FEBS Lett, 2003, 545(2/3): 144-150. ［19］ Li JM, Zhang W, Su H, et al. Reversal of multidrug resistance in MCF7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acidconjugated polyethylenimine hydroxypropylβcyclodextrin nanocarrier［J］. Int J Nanomedicine, 2015, 10: 3147-3162. DOI: 10.2147/IJN.S67146. ［20］ Tian W, Chen J, He H, et al. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications［J］. Clin Transl Oncol, 2013, 15(5): 335-342. DOI: 10.1007/s1209401209295. ［21］ Hu Y, Xu K, Yagüe E. miR218 targets survivin and regulates resistance to chemotherapeutics in breast cancer［J］. Breast Cancer Res Treat, 2015, 151(2): 269-280. DOI: 10.1007/s1054901533729. ［22］ Milane L, Ganesh S, Shah S, et al. Multimodal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology［J］. J Control Release, 2011, 155(2): 237-247. DOI: 10.1016/j.jconrel.2011.03.032. ［23］ He Q, Shi J. MSN anticancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition［J］. Adv Mater, 2014, 26(3): 391-411. DOI: 10.1002/adma.201303123. ［24］贾晋斌, 韦青燕. 阿霉素脂质体的研究进展［J］. 中国肿瘤, 2011, 20(5): 372-377. DOI: 10.1063/1.3253351. ［25］ Huang C, Li Y, Cao P, et al. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycinresistant SGC7901/ADM gastric cancer cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 488-496. DOI: 10.1007/s1159601104780. ［26］ Mao Z, Zhou J, Luan J, et al. Tamoxifen reduces Pgpmediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ERnegative human gastric cancer cells［J］. Biomedicine Pharmacother, 2014, 68(2): 179-183. DOI: 10.1016/j.biopha.2013.10.003.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Reversing methods of tumor multidrug resistance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价